Payment overview · 2025
General Payments
$234.29
12 reported records · 6 companies
Healthcare provider profile · identity verified
Tara Mcnally, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · CLEARWATER, FL · NPI 1619104072
Verified facts
What the public records show
CMS Open Payments records show Tara Mcnally, NP received $234.29 in general payments during 2025 across 12 reported records.
Amgen Inc. accounted for 31.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Trelegy Ellipta.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Prolia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $72.85 | 31.1% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $50.09 | 21.4% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $46.45 | 19.8% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $24.08 | 10.3% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $21.91 | 9.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.91 | 8.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $234.29 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $72.85 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $72.85 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $50.09 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $46.45 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $24.08 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $24.08 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $21.91 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.91 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.91 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 450 | 142 |
| Atorvastatin Calcium | Atorvastatin Calcium | 425 | 132 |
| Levothyroxine Sodium | Levothyroxine Sodium | 375 | 117 |
| Alprazolam | Alprazolam | 290 | 60 |
| Amlodipine Besylate | Amlodipine Besylate | 250 | 78 |
| Lisinopril | Lisinopril | 240 | 82 |
| Losartan Potassium | Losartan Potassium | 223 | 71 |
| Metformin Hcl | Metformin Hcl | 174 | 54 |
| Omeprazole | Omeprazole | 164 | 58 |
| Methylprednisolone | Methylprednisolone | 154 | 126 |
| Pantoprazole Sodium | Pantoprazole Sodium | 154 | 51 |
| Hydrochlorothiazide | Hydrochlorothiazide | 151 | 50 |
| Simvastatin | Simvastatin | 150 | 46 |
| Gabapentin | Gabapentin | 141 | 50 |
| Meloxicam | Meloxicam | 127 | 44 |
| Sertraline Hcl | Sertraline Hcl | 117 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 114 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 113 | 42 |
| Trazodone Hcl | Trazodone Hcl | 105 | 40 |
| Allopurinol | Allopurinol | 92 | 25 |
| Tramadol Hcl | Tramadol Hcl | 91 | 28 |
| Lorazepam | Lorazepam | 90 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 85 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 85 | 27 |
| Bupropion Xl | Bupropion Hcl | 84 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 83 | 25 |
| Montelukast Sodium | Montelukast Sodium | 82 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 78 | 27 |
| Furosemide | Furosemide | 71 | 27 |
| Tizanidine Hcl | Tizanidine Hcl | 64 | 36 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 61 | 16 |
| Ezetimibe | Ezetimibe | 57 | 18 |
| Alendronate Sodium | Alendronate Sodium | 56 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 56 | 15 |
| Xarelto | Rivaroxaban | 55 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 50 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 50 | 18 |
| Sumatriptan Succinate | Sumatriptan Succinate | 48 | suppressed |
| Prednisone | Prednisone | 45 | 22 |
| Azithromycin | Azithromycin | 44 | 39 |
| Diazepam | Diazepam | 42 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 42 | 12 |
| Finasteride | Finasteride | 41 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 41 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 38 | 16 |
| Temazepam | Temazepam | 38 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 37 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 37 | 13 |
| Carvedilol | Carvedilol | 36 | 14 |
| Clonazepam | Clonazepam | 36 | 12 |
| Fluconazole | Fluconazole | 35 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 35 | 12 |
| Atenolol | Atenolol | 34 | 11 |
| Eliquis | Apixaban | 34 | suppressed |
| Famotidine | Famotidine | 34 | 11 |
| Jardiance | Empagliflozin | 34 | suppressed |
| Lovastatin | Lovastatin | 34 | 11 |
| Ozempic | Semaglutide | 34 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 34 | 11 |
| Synthroid | Levothyroxine Sodium | 33 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 33 | suppressed |
| Potassium Chloride | Potassium Chloride | 32 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 32 | 31 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 25 |
| Farxiga | Dapagliflozin Propanediol | 30 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 25 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 29 | 25 |
| Mirtazapine | Mirtazapine | 29 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | suppressed |
| Glimepiride | Glimepiride | 28 | suppressed |
| Ibuprofen | Ibuprofen | 27 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 27 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Estradiol | Estradiol | 25 | suppressed |
| Nitroglycerin | Nitroglycerin | 25 | 14 |
| Sildenafil Citrate | Sildenafil Citrate | 25 | suppressed |
| Valsartan | Valsartan | 25 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 24 | 18 |
| Buspirone Hcl | Buspirone Hcl | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 22 | suppressed |
| Baclofen | Baclofen | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 20 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | 11 |
| Valacyclovir | Valacyclovir Hcl | 20 | 14 |
| Acyclovir | Acyclovir | 19 | suppressed |
| Folic Acid | Folic Acid | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 18 | suppressed |
| Eszopiclone | Eszopiclone | 18 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 12 |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Pregabalin | Pregabalin | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Cephalexin | Cephalexin | 16 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | 11 |
| Aubagio | Teriflunomide | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Prolia | Denosumab | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Trimethoprim | Trimethoprim | 12 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 11 | suppressed |
| Invokana | Canagliflozin | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
| Xanax | Alprazolam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $234.29 · 12 records | Amgen Inc. | Cologuard Collection Kit, Dexcom G6 Transmitter, MOUNJARO, OTEZLA, Ozempic, REPATHA, Rybelsus, TRELEGY ELLIPTA, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error